Free Trial

BioLife Solutions (BLFS) Competitors

BioLife Solutions logo
$26.10 0.00 (0.00%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$25.90 -0.20 (-0.77%)
As of 06/12/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BLFS vs. LIVN, MMED, NVST, IRTC, and WRBY

Should you buy BioLife Solutions stock or one of its competitors? MarketBeat compares BioLife Solutions with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioLife Solutions include LivaNova (LIVN), MiniMed Group (MMED), Envista (NVST), iRhythm Technologies (IRTC), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.

How does BioLife Solutions compare to LivaNova?

BioLife Solutions (NASDAQ:BLFS) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

LivaNova has a net margin of 7.48% compared to BioLife Solutions' net margin of -2.80%. LivaNova's return on equity of 16.48% beat BioLife Solutions' return on equity.

Company Net Margins Return on Equity Return on Assets
BioLife Solutions-2.80% 1.81% 1.65%
LivaNova 7.48%16.48%7.59%

BioLife Solutions has higher earnings, but lower revenue than LivaNova. BioLife Solutions is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$96.21M13.25-$4.59M-$0.08N/A
LivaNova$1.39B3.14-$242.47M$1.9540.71

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by company insiders. Comparatively, 0.4% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioLife Solutions has a beta of 2, indicating that its share price is 100% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

BioLife Solutions presently has a consensus price target of $32.00, indicating a potential upside of 22.61%. LivaNova has a consensus price target of $79.38, indicating a potential downside of 0.02%. Given BioLife Solutions' higher probable upside, equities analysts clearly believe BioLife Solutions is more favorable than LivaNova.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLife Solutions
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
LivaNova
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, LivaNova had 6 more articles in the media than BioLife Solutions. MarketBeat recorded 7 mentions for LivaNova and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.88 beat LivaNova's score of 0.80 indicating that BioLife Solutions is being referred to more favorably in the media.

Company Overall Sentiment
BioLife Solutions Very Positive
LivaNova Positive

Summary

LivaNova beats BioLife Solutions on 10 of the 16 factors compared between the two stocks.

How does BioLife Solutions compare to MiniMed Group?

BioLife Solutions (NASDAQ:BLFS) and MiniMed Group (NASDAQ:MMED) are both medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

MiniMed Group has higher revenue and earnings than BioLife Solutions.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$96.21M13.25-$4.59M-$0.08N/A
MiniMed Group$2.99B1.42N/AN/AN/A

MiniMed Group has a net margin of 0.00% compared to BioLife Solutions' net margin of -2.80%. BioLife Solutions' return on equity of 1.81% beat MiniMed Group's return on equity.

Company Net Margins Return on Equity Return on Assets
BioLife Solutions-2.80% 1.81% 1.65%
MiniMed Group N/A N/A N/A

BioLife Solutions presently has a consensus target price of $32.00, indicating a potential upside of 22.61%. MiniMed Group has a consensus target price of $21.33, indicating a potential upside of 40.72%. Given MiniMed Group's stronger consensus rating and higher possible upside, analysts clearly believe MiniMed Group is more favorable than BioLife Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLife Solutions
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
MiniMed Group
1 Sell rating(s)
2 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.73

93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 19.7% of MiniMed Group shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by company insiders. Comparatively, 2.2% of MiniMed Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, MiniMed Group had 3 more articles in the media than BioLife Solutions. MarketBeat recorded 4 mentions for MiniMed Group and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.88 beat MiniMed Group's score of 0.47 indicating that BioLife Solutions is being referred to more favorably in the media.

Company Overall Sentiment
BioLife Solutions Very Positive
MiniMed Group Neutral

Summary

BioLife Solutions and MiniMed Group tied by winning 6 of the 12 factors compared between the two stocks.

How does BioLife Solutions compare to Envista?

Envista (NYSE:NVST) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Envista presently has a consensus price target of $28.67, suggesting a potential upside of 16.80%. BioLife Solutions has a consensus price target of $32.00, suggesting a potential upside of 22.61%. Given BioLife Solutions' higher probable upside, analysts plainly believe BioLife Solutions is more favorable than Envista.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Envista
0 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.40
BioLife Solutions
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Envista and Envista both had 1 articles in the media. BioLife Solutions' average media sentiment score of 1.88 beat Envista's score of 0.50 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company Overall Sentiment
Envista Positive
BioLife Solutions Very Positive

93.2% of BioLife Solutions shares are held by institutional investors. 1.0% of Envista shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Envista has a net margin of 2.41% compared to BioLife Solutions' net margin of -2.80%. Envista's return on equity of 7.11% beat BioLife Solutions' return on equity.

Company Net Margins Return on Equity Return on Assets
Envista2.41% 7.11% 3.91%
BioLife Solutions -2.80%1.81%1.65%

Envista has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, BioLife Solutions has a beta of 2, meaning that its share price is 100% more volatile than the broader market.

Envista has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Envista$2.72B1.47$47M$0.4159.86
BioLife Solutions$96.21M13.25-$4.59M-$0.08N/A

Summary

Envista beats BioLife Solutions on 8 of the 14 factors compared between the two stocks.

How does BioLife Solutions compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

In the previous week, iRhythm Technologies had 4 more articles in the media than BioLife Solutions. MarketBeat recorded 5 mentions for iRhythm Technologies and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.88 beat iRhythm Technologies' score of 1.11 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company Overall Sentiment
iRhythm Technologies Positive
BioLife Solutions Very Positive

BioLife Solutions has a net margin of -2.80% compared to iRhythm Technologies' net margin of -3.53%. BioLife Solutions' return on equity of 1.81% beat iRhythm Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
iRhythm Technologies-3.53% -10.26% -1.39%
BioLife Solutions -2.80%1.81%1.65%

iRhythm Technologies currently has a consensus target price of $187.38, suggesting a potential upside of 64.88%. BioLife Solutions has a consensus target price of $32.00, suggesting a potential upside of 22.61%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, analysts clearly believe iRhythm Technologies is more favorable than BioLife Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRhythm Technologies
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
2.94
BioLife Solutions
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

iRhythm Technologies has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 2, indicating that its stock price is 100% more volatile than the broader market.

93.2% of BioLife Solutions shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by company insiders. Comparatively, 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioLife Solutions has lower revenue, but higher earnings than iRhythm Technologies. BioLife Solutions is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRhythm Technologies$747.14M5.00-$44.55M-$0.86N/A
BioLife Solutions$96.21M13.25-$4.59M-$0.08N/A

Summary

BioLife Solutions beats iRhythm Technologies on 10 of the 17 factors compared between the two stocks.

How does BioLife Solutions compare to Warby Parker?

BioLife Solutions (NASDAQ:BLFS) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

BioLife Solutions has a beta of 2, indicating that its share price is 100% more volatile than the broader market. Comparatively, Warby Parker has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

Warby Parker has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$96.21M13.25-$4.59M-$0.08N/A
Warby Parker$871.91M3.23$1.64M$0.021,316.20

93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 93.2% of Warby Parker shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by insiders. Comparatively, 16.8% of Warby Parker shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Warby Parker has a net margin of 0.15% compared to BioLife Solutions' net margin of -2.80%. Warby Parker's return on equity of 2.30% beat BioLife Solutions' return on equity.

Company Net Margins Return on Equity Return on Assets
BioLife Solutions-2.80% 1.81% 1.65%
Warby Parker 0.15%2.30%1.18%

BioLife Solutions currently has a consensus price target of $32.00, suggesting a potential upside of 22.61%. Warby Parker has a consensus price target of $29.50, suggesting a potential upside of 12.07%. Given BioLife Solutions' higher possible upside, research analysts clearly believe BioLife Solutions is more favorable than Warby Parker.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLife Solutions
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Warby Parker
0 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.64

In the previous week, Warby Parker had 4 more articles in the media than BioLife Solutions. MarketBeat recorded 5 mentions for Warby Parker and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.88 beat Warby Parker's score of 0.33 indicating that BioLife Solutions is being referred to more favorably in the media.

Company Overall Sentiment
BioLife Solutions Very Positive
Warby Parker Neutral

Summary

Warby Parker beats BioLife Solutions on 10 of the 15 factors compared between the two stocks.

Get BioLife Solutions News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLFS vs. The Competition

MetricBioLife SolutionsMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$1.28B$8.31B$6.53B$12.05B
Dividend YieldN/A2.50%2.67%5.67%
P/E Ratio-326.2115.6424.2224.42
Price / Sales13.257.06511.60109.90
Price / Cash113.9817.4427.4837.92
Price / Book3.383.6210.656.82
Net Income-$4.59M$224.06M$3.57B$337.56M
7 Day PerformanceN/A-1.40%0.58%1.17%
1 Month Performance25.72%4.39%1.54%3.16%
1 Year Performance18.47%-0.88%25.40%30.58%

BioLife Solutions Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BLFS
BioLife Solutions
3.3514 of 5 stars
$26.10
flat
$32.00
+22.6%
+18.5%$1.28B$96.21MN/A440
LIVN
LivaNova
2.0418 of 5 stars
$77.43
+3.5%
$79.38
+2.5%
+73.5%$4.22B$1.39B39.393,300
MMED
MiniMed Group
4.3966 of 5 stars
$15.19
+2.1%
$21.33
+40.4%
N/A$4.22B$2.99BN/A8,000
NVST
Envista
2.4162 of 5 stars
$24.18
+3.2%
$28.83
+19.2%
+33.1%$3.89B$2.72B58.3612,000
IRTC
iRhythm Technologies
4.3412 of 5 stars
$110.04
+2.6%
$189.69
+72.4%
-21.0%$3.59B$747.14MN/A2,400

Related Companies and Tools


This page (NASDAQ:BLFS) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners